We observed a high rate of DTC-eradication among baseline DTC-positive breast cancer patients after NACT ± denosumab (73.2%), which was consistent across the different subtypes of breast cancer (73.3% in HR + /HER2-; 70.0% in HER2 + ; 75.0% in TNBC; p = 0.961; Fig. 2C). This evidence concerns the gene ERBB2 and breast carcinoma.